Effects of central muscarinic-1 receptor stimulation on blood pressure regulation

Hypertension

Volumn 29, Issue 3, 1997, Pages 828-834

  Medina, Aharon ^b   Bodick, Neil ^b   Goldberger, Ary L ^b   Mac Mahon, Margaret ^b   Lipsitz, Lewis A ^a  

^a RESEARCH AND TRAINING INSTITUTE   (United States)

^b NONE

Author keywords

aging; Alzheimer's disease; neurotransmitters; orthostatic hypotension; syncope; tilt; xanomeline

Indexed keywords

MUSCARINIC M1 RECEPTOR AGONIST; PLACEBO; XANOMELINE;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD PRESSURE REGULATION; BODY POSTURE; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MALE; NEUROTRANSMISSION; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; SYNCOPE;

EID: 0031026661     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.29.3.828     Document Type: Article

References (36)

1. van Zwieten PA, Doods HN. Muscarinic receptors and drugs in cardiovascular medicine. Cardiovasc Drugs Ther. 1995;9:159-167.
2. van Zwieten PA, Hendriks MGC, Pfaffendorf M, Bruning TA, Chang PC. The parasympathetic system and its muscarinic receptors in hypertensive disease. Hypertension. 1995;13:1079-1090.
3. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI, for the Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA. 1994;271:985-991.
4. 1 muscarinic agonist xanomeline (LY246708/NNC11-0232). J Pharmacol Exp Ther. 1994;269:282-289.
5. 1 receptors. J Pharmacol Exp Ther. 1994;269:271-281.
6. Lilly Research Laboratories. Clinical Investigator's Brochure, Part I: Xanomeline Tartrate. 1996;section 10:1-3.
7. Brezenoff HE, Giuliano R. Cardiovascular control by cholinergic mechanisms in the central nervous system. Annu Rev Pharmacol Toxicol. 1982;22:341-381.
8. Brezenoff HE, Xiao YF. Acetylcholine in the posterior hypothalamic nucleus is involved in the elevated blood pressure in the spontaneously hypertensive rat. Life Sci. 1989;45:1163-1170.
9. Martin JR. Pressor response to posterior hypothalamic administration of carbachol is mediated by muscarinic M3 receptor. Eur J Pharmacol. 1992;215:83-91.
10. Scheucher A, Pirola CJ, Balda MS, Dabsys SM, Alvarez AL, Finkielman S, Nahmod VE. Muscarinic M1 receptors in the lateral septal area mediate cardiovascular responses to cholinergic agonists and bradykinin: supersensitivity induced by chronic treatment with atropine. Neuropharmacology. 1987;26:181-185.
11. Saito Y. Effect of a muscarinic (M1) receptor agonist on sympathetic nerve activity in rats. Hokkaido Igaku Zasshi. 1993;68:190-204.
12. Taira CA, Enero MA. Central muscarinic involvement in cardiovascular control in sinoaortic-denervated rats. Eur J Pharmacol. 1989;159:265-272.
13. Saito K, Yoshioka M, Kohya T, Kitabatake A. Involvement of muscarinic M1 receptor in the central pathway of the serotonin-induced Bezold-Jarisch reflex in rats. J Auton Nerv Syst. 1994;49:61-68.
14. Bonner TI, Buckley NJ, Young AC, Brann MR. Identification of a family of muscarinic acetylcholine receptor genes. Science. 1987; 237:527-532.
15. Hulme EC, Birdsall NJM, Buckley NJ. Muscarinic receptor subtypes. Annu Rev Pharmacol Toxicol. 1990;30:633-673.
16. Giacobini E. Cholinergic receptors in human brain: effects of aging and Alzheimer's disease. J Neurosci Res. 1990;27:548-560.
17. Sversson AL, Alufusoff I, Nordberg A. Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists. Brain Res. 1992;396:142-148.
18. Mash DC, Flynn DD, Potter LT. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science. 1985;228:1115-1117.
19. Vitiello B, Veith RC, Molchan SE, Martinez RA, Lawlor BA, Radcliffe J, Hill JL, Sunderland T. Autonomie dysfunction in patients with dementia of the Alzheimer type. Biol Psychiatry. 1993;34:428-433.
20. Burke WJ, Coronadi PG, Schmitt CA, Gillespie KM, Chung HD. Blood pressure regulation in Alzheimer's disease. J Auton Nerv Syst. 1994;48:65-71.
21. Brown JH. Atropine, scopolamine, and related antimuscarinic drugs. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 1990:150-165.
22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
23. Jansen RWMM, Lipsitz LA. Postprandial hypotension: epidemiology, pathophysiology, and clinical management. Ann Intern Med. 1995;122:286-295.
24. Lipsitz LA, Stollar C. Revised standard study meal. Ann Intern Med. 1995;123:158. Letter.
25. Whitney RJ. The measurement of volume changes in human limbs. J Physiol Lond. 1953;121:1-27.
26. Moody GB, Mark RG. The MIT-BIH Arrhythmia Database on CD-ROM and software for use with it. In: Ripley KL, ed. Computers in Cardiology. Los Alamos, NM: IEEE Computer Society Press; 1990:185-188.
27. Lipsitz LA, Mietus J, Moody GB, Goldberger AL. Spectral characteristics of heart rate variability before and during postural tilt: relations to aging and risk of syncope. Circulation. 1990;81: 1803-1810.
28. Kapoor WN, Brant N. Evaluation of syncope by upright tilt testing with isoproterenol. Ann Intern Med. 1992;116:358-363.
29. Brezenoff HE. Cardiovascular regulation by brain acetylcholine. Fed Proc. 1984;43:17-20.
30. Janowsky DS, Risch C, Huey LY. Central cardiovascular effects of physostigmine in humans. Hypertension. 1985;7:140-145.
31. 2 adrenergic agents injected into the nucleus tractus solitarii. Naunyn Schmiedebergs Arch Pharmacol. 1987;335: 274-277.
32. 2-adrenoceptors and brain cholinergic stimulation in sinoaortic denervated rats. Eur J Pharmacol. 1994;271:9-16.
33. Robinson SE. Serotonergic-cholinergic interactions in blood pressure control in the rat. Fed Proc. 1984;43:21-24.
34. Nutt J, Rosin A, Chase TN. Treatment of Huntington's disease with a cholinergic agonist. Neurology. 1978;78:1061-1064.
35. Meyer EC, Sommers DK. Possible mechanisms of anti-cholinergic drug-induced bradycardia. Eur J Clin Pharmacol. 1988;35:503-506.
36. Mark AL. The Bezold-Jarisch reflex revisited: clinical implications of inhibitory reflexes originating in the heart. J Am Coll Cardiol. 1983;1:90-102.